Kiniksa PharmaceuticalsKNSA
13F holders, Q4 2024 (December 31)2holders
0new positions
0sold out
$19.78avg. 13F price*
At the end of Q4 2024, 2 institutions reported holding Kiniksa Pharmaceuticals Ltd. (KNSA) in their 13F filings, unchanged from Q3 2024. 0 opened new positions and 0 sold out. The largest holders were Harbor Capital Advisors, Inc. ($1.9M) and Birchview Capital, LP ($593K).
- Company
- Kiniksa Pharmaceuticals Ltd.
- CUSIP
- G5269C101
- Latest filing quarter
- Q1 2026
History
Number of 13F holders
Total Exit/New Position Q3 2024 → Q4 2024
| Institutions | Total Value | |
|---|---|---|
| New Positions | 0 | $0 |
| Exits | 0 | $0 |
All 13F filers, Q3 2024 → Q4 2024: 550 shares bought, net +550 shares. Counts holders who added, trimmed, opened or closed a position; split-adjusted.
Ownership 2 holders
| Harbor Capital Advisors, Inc. | 0.08% | Add +0.6% | 98,093 | $1.9M |
| Birchview Capital, LP | 0.48% | No change | 30,000 | $593K |
"% of holder's portfolio" is KNSA's weight in each manager's 13F, not the share of Kiniksa Pharmaceuticals Ltd. the manager owns.